Trial Profile

A phase I/II study of INM-088 for the treatment of glaucoma

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabinol (Primary) ; Cannabinol (Primary)
Indications Glaucoma
Focus Adverse reactions
Sponsors InMed Pharmaceuticals

Most Recent Events

10 Jan 2023 According to an InMed Pharmaceuticals media release, several additional prospective patients have been identified for screening at the clinical sites; therefore, the Company decided to extend the enrollment period to the end of March 2023.
10 Jan 2023 According to an InMed Pharmaceuticals media release, company has completed a pre-Investigational New Drug application meeting with the FDA and gained alignment on the proposed design for this trial.
23 Sep 2022 According to an InMed Pharmaceuticals media release, the company expects to file regulatory applications in the first half of the calendar year 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com